← All trials
NCT07051915
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2025
- Primary completion
- Jan 31, 2028
- Completion date
- Dec 31, 2029
- First posted
- Jul 4, 2025
- Last posted
- Sep 9, 2025
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- South-Eastern Norway Regional Health AuthorityLead sponsor
- Sykehuset i Vestfold HFCollaborator
- University Hospital of North NorwayCollaborator
- Helse FonnaCollaborator
- Oslo Metropolitan UniversityCollaborator
- University of StavangerCollaborator
- University of OsloCollaborator
- Northern Norway Regional Health AuthorityCollaborator
- University of BergenCollaborator
- Sorlandet Hospital HFCollaborator
- Nordland HospitalCollaborator
- Norwegian University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.